Reproductive, Developmental, and Genetic Toxicology of Ioversol

Ralston, William; Robbins, Mark S.; James, Penny A.

doi:10.1097/00004424-198906001-00004

Cited by 21 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo tests in animals have shown no evidence of either mutagenic or teratogenic effects with the nonionic iodinated agents [5][6][7][8][9][10][11][12].…”

Section: Mutagenicity and Teratogenicity Of Contrast Mediamentioning

confidence: 99%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

The use of iodinated or gadolinium-based contrast media in pregnant or lactating women often causes concerns in the radiology department because of the principle of not exposing a fetus or neonate to any drugs. Because of the uncertainty about the use of contrast media during pregnancy and lactation, the Contrast Media Safety Committee of the European Society of Urogenital Radiology decided to review the literature and draw up guidelines. An extensive literature search was carried out and summarized in a report. Based on the limited information available, simple guidelines have been drawn up. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela, Spain. Mutagenic and teratogenic effects have not been described after administration of gadolinium or iodinated contrast media. Free iodide in radiographic contrast medium given to the mother has the potential to depress fetal/neonatal thyroid function. Neonatal thyroid function should be checked during the 1st week if iodinated contrast media have been given during pregnancy. No effect on the fetus has been seen after gadolinium contrast media. Only tiny amounts of iodinated or gadolinium-based contrast medium given to a lactating mother reach the milk, and only a minute proportion entering the baby's gut is absorbed. The very small potential risk associated with absorption of contrast medium may be considered insufficient to warrant stopping breast-feeding for 24 h following either iodinated or gadolinium contrast agents.

show abstract

“…In vivo tests in animals have shown no evidence of either mutagenic or teratogenic effects with the nonionic iodinated agents [5][6][7][8][9][10][11][12].…”

Section: Mutagenicity and Teratogenicity Of Contrast Mediamentioning

confidence: 99%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

show abstract

“…Animal studies have not shown teratogenic effects. 37,38 Although iodinated agents can produce neonatal hypothyroidism, such effects have not been reported from intravascular use. 39 The toxicity of gadolinium is not known; however, deposition of the gadolinium ions in fetal tissue raises concern.…”

Section: Issues Related To Contrast Agent Exposurementioning

confidence: 99%

Stroke in Pregnancy

Feske

2007

Semin Neurol

View full text Add to dashboard Cite

Although pregnancy-associated stroke is uncommon, the risk of stroke is greatly increased above the low baseline rate in young patients during late pregnancy and, even more so, during the puerperium. Stroke is a major contributor to the serious morbidity and mortality of pregnancy. The physiological hormonally mediated changes in circulation, vascular tissue structure, and coagulability, and the pathological state of pre-eclampsia-eclampsia contribute to this increased risk of stroke. Pregnancy-associated strokes are roughly evenly divided among hemorrhagic strokes, mainly from rupture of aneurysms and arteriovenous malformations (AVMs); ischemic strokes, mainly from late pregnancy and postpartum cerebral venous thrombosis; and strokes associated with pre-eclampsia-eclampsia, with a contribution from cardioembolism, especially in populations at risk from a high rate of underlying rheumatic valvular heart disease. Awareness of the types of stroke to expect during pregnancy will facilitate early diagnosis. This article discusses the pathogenesis of pregnancy-associated stroke, its epidemiology, and some diagnostic and therapeutic issues unique to pregnancy.

show abstract

“…Another problem raised is the use of contrast agents. There were no teratogenetic / mutation effects in in vivo studies (61,62). Using iodinated contrast was thought to have a potential in developing hypothyroidism to the foetus (63,64), but these reluctances were eliminated through newer studies (65,66), which have not found any side effect of the child's thyroid function after the exposure to these substances during the foetal period.…”

Section: Computed Tomography (Ct)mentioning

confidence: 99%

Pancreatic Neuroendocrine Tumour in Pregnancy - Diagnosis and Treatment Management

Predescu¹

2019

chr

View full text Add to dashboard Cite

Diagnosis and Treatment Management Chirurgia, 114 (5), 2019 www.revistachirurgia.ro 551 investigaţii sau alteia revenind trimestrului de graviditate. Precauţia legată de "compromiterea" fetală în indicarea unei explorări invazive (imagistice, endoscopice, etc) întârzie de asemenea diagnosticul. Caracterul puţin agresiv, mai de curând cu potenţial benign face ca prognosticul insulinoamelor să fie în general unul favorabil iar posibilităţile terapeutice uşor de administrat şi controlat la gravide. Tratamentul medical se adresează pacientelor atunci când există diagnostic pozitiv dar nu putut identifica topografia insulinomului, când simptomatologia este uşor controlată prin terapie conservatoare până când se obţine o vârstă convenabilă a fătului fie imediat postpartum, la gravidele care refuză intervenţia chirurgicală, fie în stadiul metastatic al insulinomului malign. Tratamentul chirurgical rămâne cu adevărat singura modalitate de rezolvare terapeutică dar, cel mai adesea, sub forma unei chirurgii programate, de regulă post-partum, sau dacă situaţia "forţează" indicaţia, cât mai târziu după o vârstă fetală convenabilă (după 28 săptămâni). Cuvinte cheie: neoplazia neuroendocrinã pancreaticã, sarcinã, managementul de diagnostic şi tratament

show abstract

Reproductive, Developmental, and Genetic Toxicology of Ioversol

Cited by 21 publications

References 0 publications

The use of iodinated and gadolinium contrast media during pregnancy and lactation

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Stroke in Pregnancy

Pancreatic Neuroendocrine Tumour in Pregnancy - Diagnosis and Treatment Management

Contact Info

Product

Resources

About